Hilltop Bio is a veterinary biotech company developing innovative, custom engineered regenerative therapies focused on helping our four-legged friends reduce inflammation from injuries or disease.
When lifelong horse rider, Amanda Drobnis, suffered a serious hip injury at the age of 29, her doctors gave her two options: a full hip replacement or an experimental amnion based treatment. Ever curious about the latest advancements in science and regenerative medicine, Amanda chose to experiment. Within a few weeks of treatment she was back on her feet, and not long after that she was back in the saddle. Her recovery was so remarkable, in fact, that her hip felt better than it had before the injury.
After personally experiencing the extraordinary benefits of regenerative therapy, Amanda dedicated herself to using the same scientific advancements and technology to develop products for equine and companion animal patients. And thus, Hilltop Bio was established, with Amanda at the helm as CEO, and with her partner, Mark Williams, as VP of Business Development
The company’s strategy is to identify key inflammatory conditions in horses and companion animals and produce targeted regenerative therapies to help reduce inflammation and normalize the damaged tissue function. Hilltop Bio has developed a strong pipeline of innovative therapies within cGMP/cGTP manufacturing standards, and has a growing intellectual property portfolio across many therapeutic classes.
In an industry heavily dominated by men, women make up more than half of Hilltop Bio’s professional team. The company is proud to work with some of the leading female scientists and veterinarians in the country who are focused on advancing animal health. We are committed not only to researching and creating products with the latest scientific and technological advancements available today, but also to developing a company where women are championed and work culture and professional development matter.